Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
<p><strong>Background</strong> Despite widespread searches, there are currently no validated biofluid markers for the detection of subclinical neuroinflammation in multiple sclerosis (MS). The dynamic nature of human metabolism in response to changes in homeostasis, as measured by...
Autores principales: | Yeo, T, Bayuangga, H, Augusto-Oliveira, M, Sealey, M, Claridge, TDW, Tanner, RL, Leppert, D, Palace, J, Kuhle, J, Probert, F, Anthony, DC |
---|---|
Formato: | Journal article |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Ejemplares similares
-
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
por: Yeo, Tianrong, et al.
Publicado: (2022) -
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
por: Probert, F, et al.
Publicado: (2021) -
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
por: Yeo, T, et al.
Publicado: (2021) -
Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
por: Probert, F, et al.
Publicado: (2022) -
A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application
por: Yeo, T, et al.
Publicado: (2020)